Table 2. Cell Cycle Analysis of cell lines treated with SL analogues.
Cell Line | SL (dose/ppm) | SubG1/poptosis | Cell Cycle Distribution (%) | ||
---|---|---|---|---|---|
| |||||
G1 | S | G2 | |||
| |||||
BJ fibroblast | Vehicle | 0.21 | 84.25 | 2.510 | 10.17 |
EGO5 (10) | 0.49 | 82.29 | 4.480 | 10.50 | |
ST362 (5) | 0.72 | 83.42 | 1.580 | 12.86 | |
MEB55 (5) | 0.57 | 78.96 | 5.930 | 11.54 | |
| |||||
MDA-MB-231 | Vehicle | 0.41 | 60.43 | 13.02 | 24.08 |
EGO5 (10) | 11.32 | 34.74 | 14.59 | 35.70 | |
ST362 (5) | 4.17 | 42.17 | 11.90 | 37.93 | |
MEB55 (5) | 3.88 | 49.61 | 14.51 | 28.33 |